MediWound, Ltd. (MDWD): חובות להיוון בספרים
The advanced wound care sector is characterized by rigorous efficiency benchmarks, where MediWound Ltd. (MDWD) contends with the expansion of global medical behemoths. The business relies on the production of skin restoration enzymes, while government contracts and patents ensure high margins and steady cash flow. The asset's price trajectory, currently at 0.28, prices in the promotion costs for NexoBrid and uncertainty regarding deals with BARDA.
mediwound.com (MDWD) - פילוחי מדדים ודוחות פיננסיים
A steady influx of capital from US defense contracts and wound healing product sales allows MediWound Ltd. (MDWD) to maintain high liquidity. The current value of 0.28 reflects the share of total liabilities within the equity structure, helping investors assess the level of financial leverage and business stability via the debt-to-book capitalization ratio.